The results position these cancers as favorable candidates for anti-IL-1β therapy, and versican as a diagnostic and prognostic biomarker, as well as a therapeutic target in this tumor category that comprises 9% of all human cancers, alone or in combination with anti-IL-1β agents. Here, VCAN is linked to cancer.